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Education and debate
Hormone replacement therapy and breast cancer: estimate
of risk
Nathan J Coombs, Richard Taylor, Nicholas Wilcken, John Boyages
Patients often ask how population risk data apply to them. This analysis will help doctors to answer
that question for women considering hormone replacement therapy
The risk of breast cancer arises from a combination of
genetic susceptibility and environmental factors.
Recent studies show that type and duration of use of
hormone replacement therapy affect a women’s risk of
developing breast cancer.1–7 The women’s health initia-
tive trial was stopped early because of excess adverse
cardiovascular events and invasive breast cancer with
oestrogen and progestogen.6 The publicity increased
public awareness of the risks of hormone replacement
therapy, and this was heightened by the publication of
the million women study.2 However, the recently
published oestrogen only arm of the women’s health
initiative trial suggests that this formulation may
reduce the risk of breast cancer.8 To help make sense of
the often confusing information,9 women and clini-
cians need individual rather than population risk data.
We have produced estimates that can be used to calcu-
late individual risk for women living up to the age of 79
and suggest the risk may be lower than is often
thought.
Importance of individual data
Fears about the risks of hormone replacement therapy
have resulted in reduced use.10–12 Without individual
risk data, however, it is difficult to weigh the benefits
and harms of treatment accurately, and many women
may have stopped treatment unnecessarily.
Although data on the lifetime risk of breast cancer
(from birth to average life expectancy) are available,
these are of limited value in the clinical context. This is
because cumulative absolute risk declines as years of
remaining life diminish, even though the age specific
risk increases.13 The influence of hormone replace-
ment therapy and other factors on absolute risk may
be less in an elderly population because the number of
years remaining at risk is fewer than in a younger
population.
Calculation of risk
We used the attributable fraction method to estimate
the cumulative absolute risk of breast cancer from vari-
ous ages to 79 years (average life expectancy) in
relation to hormone replacement therapy. This
technique has been used to calculate the risks of
disease for breast cancer related to family history13 and
for smokers and non-smokers14 15 and is described in
more detail elsewhere.16 17
Our calculations are based on existing data on use
of hormone replacement therapy and risk of breast
cancer. We estimated the use of hormone replacement
therapy from the latest quinquennial Australian health
survey (in 2001). We extrapolated the data to provide
estimates of proportion and duration of use (no use,
< 1 year, 1-5 years, 6-10 years, ≥ 10 years) for the entire
Australian population by five year age group. In 2001,
11.7% of women (aged 18–80) were taking hormone
replacement therapy, with highest use in 55-59 year
olds (38%). Over two thirds of these women had been
taking hormone replacement therapy for at least five
years (see table A on bmj.com).
The annual incidence of breast cancer in Australia
is about 11 000 new cases a year, of which over 4000
are diagnosed in New South Wales. We retrieved
incidence data from the Cancer Council New South
Data used in the calculations are on bmj.com
Risk from hormone replacement therapy increases with duration of
treatment
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Wales website (www.nswcc.org.au). Previous studies
have estimated the “underlying” incidence of breast
cancer and the incidence attributable to breast screen-
ing.13 18 We applied these age specific screening effects
to derive the 2001 underlying breast cancer incidence
and the cumulative breast cancer risk of the population
to age 79 years (table B on bmj.com). We then used
data from the million women study (table C on
bmj.com)2 5 6 to provide specific relative risks according
to type of hormone replacement therapy and duration
of use.
The attributable factor (AF) is the proportion of the
disease due to a particular factor. We calculated the
attributable factor for hormone replacement therapy
in breast cancer for each age group by the indirect
method19 from the specific prevalence and proportions
of use and type of hormone replacement therapy20 21
and the published relative risk (RR) of breast cancer by
type and duration of use.2
AF =
p (RR − 1)
p (RR − 1)+1
where p = prevalence of use × proportion using
relevant type of hormone replacement therapy.
The attributable factors specific for type and dura-
tion of use of hormone replacement therapy for each
age group can be summed and applied to a
population. We calculated the breast cancer incidence
and cumulative absolute risk in never users of
hormone replacement therapy (Inever) from the underly-
ing incidence of breast cancer in New South Wales (Ipop)
using the direct method.19
AF =
Ipop − Inever
I
pop
We estimated the age specific breast cancer
incidence for women who had never taken hormone
replacement therapy and applied relative risks (from
the million women study2). These incidences were
summed and converted to cohort probabilities as
cumulative risks over particular age ranges.16
Cumulative risk = 1–e ( − cumulative rate)
We calculated cumulative risks from decade and
mid-decade ages to age 79 years, roughly the life
expectancy at birth of Australian women at the begin-
ning of the 21st century.
Size of risk
The average baseline risk (from 40 to 79 years) is about
7.2% (1 in 14), reducing to 6.1% (1 in 16) at 50 years,
and 4.4% (1 in 23) at 60 years (table). Use of oestrogen
only hormone replacement or short term (about five
years) use of combined therapy starting at age 50 years
hardly affects the cumulative breast cancer risk
calculated to the age of 79 (no use 6.1%, oestrogen only
6.3%, combined 6.7%). Use of combined hormone
replacement therapy for about 10 years increases the
cumulative risk to 7.7%.
Oestrogen only formulations have a minimal effect
on risk of breast cancer, even with extended use. A 55
year old woman has a cumulative absolute breast can-
cer risk to age 79 years of 5.3% (1 in 19). The additional
risk is 0.2% with five years’ use of oestrogen only hor-
mone replacement therapy, 0.5% with 10 years, and
0.9% with 15 years.
The additional breast cancer risk is greater with
combination therapy, especially if taken for more than
five years. Five years’ use, starting at age 55, generates
an extra 0.6% breast cancer risk and 10 years a further
1.8% risk. Once hormone replacement therapy is
stopped the relative risk quickly returns to 1.0 and the
cumulative absolute risk of breast cancer returns to
that of an age matched never user.
Applicability of estimates
Our derivation of absolute risk from a population inci-
dence uses an established method.16 Application of the
absolute risk to an individual assumes the woman is
representative of the population from which the
incidence data are drawn. The use of cumulative risks is
similar to actuarial life table methods and is useful for
quantifying what may happen to a hypothetical cohort
if it passed through the age specific rates used in the
calculations.
The relative risks of hormone replacement therapy
that we used have been criticised for being overstated
because of detection bias.9 They are similar, however, to
those reported in recent trials, meta-analyses, and
older cohort studies.1 4–6 The relative risk is not
influenced by local incidence of breast cancer and thus
should apply to an Australian population. Data from
the million women study have small standard errors
and allowed us to produce results according to formu-
lation and duration of use. The study also showed that
once hormone replacement therapy has been stopped,
Cumulative absolute risk and additional risk of breast cancer with duration of use of hormone replacement therapy
Age at
calculation
(years)
Age
range
(years)
Risk with no hormone
replacement therapy
Additional risk (%) with combination therapy*
(years of use)
Additional risk (%) with oestrogen only therapy*
(years of use)
Ratio† % 3 years 5 years 10 years 15 years 3 years 5 years 10 years 15 years
40 40–79 1 in 14 7.21 0.18 0.38 1.18 2.22 0.05 0.12 0.34 0.64
45 45–79 1 in 15 6.76 0.26 0.52 1.45 2.54 0.07 0.15 0.41 0.73
50 50–79 1 in 16 6.10 0.31 0.60 1.59 2.82 0.09 0.18 0.45 0.81
55 55–79 1 in 19 5.30 0.33 0.64 1.76 3.17 0.09 0.19 0.50 0.91
60 60–79 1 in 23 4.44 0.37 0.73 2.01 3.51 0.10 0.21 0.57 1.00
65 65–79 1 in 29 3.48 0.42 0.84 2.19 3.27 0.12 0.25 0.62 0.91
70 70–79 1 in 42 2.37 0.47 0.88 1.84 — 0.13 0.25 0.50 —
75 75–79 1 in 88 1.14 0.43 0.58 — — 0.12 0.14 — —
*The additional risk for a specific formulation and duration of use can be added to the baseline risk with no hormone therapy to provide an estimate of a woman’s
specific cumulative absolute risk of breast cancer from a specific age to age 79 years.
†The ratio is calculated as the reciprocal of the cumulative absolute breast cancer risk (%) of non-users.
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a woman’s breast cancer risk quickly returns almost to
1.0.2 Therefore, a woman’s cumulative absolute breast
cancer risk returns to that of the population once
treatment stops.
The data on use of hormone replacement therapy
from the Australian health survey questionnaire are
similar to those reported in UK, US, and European
surveys.22–24 Although the survey did not identify the
type of hormone replacement therapy used, other
studies estimate one half of Australian, European, or
American women taking hormone replacement
therapy are taking combined preparations.2 20 21 25–27
Implications for use
Recent publicity has heightened anxiety about the risks
of hormone replacement therapy, but absolute risk of
developing breast cancer for an individual may not be
as high as assumed. Stopping hormone replacement
therapy early because of anxiety about the risks may
reduce quality of life. Conversely, other women may
underestimate their additional cancer risk and
continue to take hormone replacement therapy.
Although we found the additional breast cancer
risk with hormone replacement therapy for an
individual is very small, the effect on the general
incidence of breast cancer would be greater, especially
in populations with a higher prevalence of use. The
indications for hormone replacement therapy vary
and decisions regarding its use must be made at
an individual level. Our analysis provides women and
clinicians with better information to make these
choices.
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Summary points
Information about risk of breast cancer with
hormone replacement therapy is conflicting
Data that can be used to derive individual risk are
presented to help decision making
Cumulative absolute risk of breast cancer
(to 79 years) falls with increasing age in women
who do not take hormone replacement
therapy
Use of hormone replacement therapy increases a
woman’s cumulative risk only slightly
The effect on the general incidence of breast
cancer incidence would be greater
Endpiece
A difficult question
We have to ask ourselves whether medicine is to
remain a humanitarian and respected profession
or a new but depersonalised science in the service
of prolonging life rather than diminishing human
suffering.
Elisabeth Kubler-Ross (b 1926), Swiss born
American psychiatrist
Submitted by Sandeep Goyal, New Delhi
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